Horizon Pharma receives marketing authorization for DUEXIS from the United Kingdom medicines and Healthcare Products Regulatory Agency Co announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for DUEXIS (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners.

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.

Read more In play articles